课题基金 / 基金详情

COBRE: HIF-1 AS THERAPEUTIC TARGET IN DIABETIC RETINOPATHY

COBRE: HIF-1 AS THERAPEUTIC TARGET IN DIABETIC RETINOPATHY
COBRE:HIF-1 作为糖尿病视网膜病变的治疗靶点
批准号:
7381937
负责人:
Michael A. Ihnat
金额:
$10.73万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-07-01 至 2007-06-30

项目摘要

项目成果

Michael A. Ihnat的其他基金

相似基金

相关文献

中文摘要
翻译
该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者(PI)可能从另一个NIH来源获得了主要资金,因此可以在其他CRISP条目中表示。所列机构为中心,不一定是研究者所在机构。糖尿病视网膜病变是糖尿病的主要并发症,也是导致失明的主要原因。在其后期阶段,这种疾病的特征在于视网膜血管的过度增殖或血管生成。缺氧诱导因子-1(Hypoxia inducible factor-1,HIF-1)是一种在缺氧条件下被快速诱导的转录因子,可调节血管生成和葡萄糖调节的关键基因的表达。HIF-1已被证明在视网膜中响应于缺氧和晚期糖基化产物(AGEs)(与糖尿病相关的改变的大分子)而显著增加。驱动这些研究的总体假设是,通过特异性破坏HIF-1抑制血管生成是潜在控制增殖性视网膜病变的新的早期靶点。具体目标一的目标是通过使用核酶或RNA的催化片段在信使RNA水平靶向HIF-1 α(HIF-1的关键亚基)。具体目标二是利用噬菌体肽展示技术寻找HIF-1 α和HIF-1 β(ARNT)亚基之间相互作用的特异性肽抑制剂。核酶和肽都将使用腺病毒局部引入视网膜。将使用氧诱导的小鼠缺血模型来检查这些药剂对血管生成和对HIF-1(VEGF,PA 1 - 1)的下游靶标的作用。使用这些分子方法,我们试图确定HIF-1在增殖性糖尿病视网膜病变中的作用,并确定这种转录因子是否代表这种疾病状态下治疗的有效靶点。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Diabetic retinopathy is a major complication of diabetes and a leading cause of blindness. In its later stages this disease is characterized by a hyperproliferation of retinal blood vessels, or angiogenesis. Hypoxia inducible factor -1 (HIF-1) is a transcription factor that is rapidly induced in response to hypoxia and regulates the expression of several genes critical to angiogenesis and glucose regulation. HIF-1 has been shown to be significantly increased in the retina in response to hypoxia and to advanced glycation products (AGEs), altered macromolecules associated with diabetes. The overall hypothesis driving these studies is that inhibition of angiogenesis through the specific disruption of HIF-1 is a novel, early target for potentially controlling proliferative retinopathy. The goal of specific aim one is to target HIF-lalpha, a critical subunit of HIF-1, at the messenger RNA level through the use of ribozymes, or catalytic pieces of RNA. The goal of specific aim two is to find specific peptide inhibitors of the interaction between the HIF-lalpha and the HIF-1beta (ARNT) subunit using phage peptide display. Both the ribozymes and the peptides will be introduced locally into the retina using adenovirus. The effect of these agents on angiogenesis and on downstream targets of HIF-1 (VEGF, PAl-l) will be examined using an oxygen-induced mouse ischemia model. Using these molecular approaches we seek to define a role for HIF-1 in proliferative diabetic retinopathy and to determine whether this transcription factor represents a valid target for therapy in this disease state.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Nephrotoxic mechanisms of f low-rank coal (lignite) leachates in drinking water
Drugs Targeting Dormant Tumors as Anti-Metastatic Agents
  • 批准号:
    8338890
  • 项目类别:
  • 资助金额:
    $87.17万
  • 财政年份:
    2008
  • 负责人:
    Michael A. Ihnat
  • 依托单位:
Drugs Targeting Dormant Tumors as Anti-Metastatic Agents
  • 批准号:
    7537741
  • 项目类别:
  • 资助金额:
    $12.25万
  • 财政年份:
    2008
  • 负责人:
    Michael A. Ihnat
  • 依托单位:
Drugs Targeting Dormant Tumors as Anti-Metastatic Agents
  • 批准号:
    8203484
  • 项目类别:
  • 资助金额:
    $110.25万
  • 财政年份:
    2008
  • 负责人:
    Michael A. Ihnat
  • 依托单位:
国内基金
海外基金
降脂消斑片通过HIF-1α/PKM2信号通路介导的能量代谢重编程抑制巨噬细胞铁死亡治疗动脉粥样硬化的作用机制
miR-30c-5p通过MTDH/HIF-1α/PKM2环形反馈抑制乳腺癌进展的作用及机制研究
HIF-1α-FtL信号轴通过调控神经元铁稳态抑制NLRP3炎性小体活化在脑缺血再灌注损伤中的作用与机制研究
  • 批准号:
    JCZRLH202600706
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位:
肿瘤相关成纤维细胞通过分泌COL10A1 介导HIF1α/KLF5调控肝细胞癌上皮间质转化和血管生成拟态的机制研究
  • 批准号:
    JCZRLH202602031
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位: